Current position

Joel Greenblatt’s Vertex Pharmaceuticals (VRTX) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Gotham Asset ManagementVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ2 2012Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares182.52KHighest verified quarter-end share count
Quarters reported35Verified quarters with shares above zero
What happened?

Gotham Asset Management first reported Vertex Pharmaceuticals in Q2 2012. After an earlier exit, the position later appeared again in a verified filing. The reported position was increased and reduced across later filings. Gotham Asset Management currently reports 18.99K shares. The latest verified filing showed: Sold 9.1% of the position.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2026
Sold 9.1% of the position−1.90K shares · 18.99K shares remained
Filing context

Quarter-end price $496.73 · Estimated holding basis $358.40

Q1 2026
Sold 2.9% of the position−624 shares · 20.89K shares remained
Filing context

Quarter-end price $446.54 · Estimated holding basis $358.40

Q4 2025
Sold 1.7% of the position−377 shares · 21.51K shares remained
Filing context

Quarter-end price $453.36 · Estimated holding basis $358.40

Q3 2025
Bought 2.5% more+532 shares · 21.89K shares reported after the change
Filing context

Quarter-end price $391.64 · Estimated holding basis $358.40

Q2 2025
Sold 23.1% of the position−6.42K shares · 21.36K shares remained
Filing context

Quarter-end price $445.20 · Estimated holding basis $357.58

Q1 2025
Sold 7.8% of the position−2.33K shares · 27.78K shares remained
Filing context

Quarter-end price $484.82 · Estimated holding basis $357.58

Portfolio importance

How important is Vertex Pharmaceuticals in Gotham Asset Management’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight0.0%Q2 2026
Current rank#813of 1791 reported positions
Peak portfolio weight0.3%Q2 2017
Best historical rank#36Q3 2022
At peak importanceQ2 2017
VRTX
0.3%
Largest holding
1.0%
Cross-investor discovery

Who else owns Vertex Pharmaceuticals?

Also reported by 1 other tracked investor in their latest verified filings.

Ray DalioBridgewater Associates, LP
VRTX0.0% of reported portfolio
Explore Vertex Pharmaceuticals across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$514.632026-09-15

Market context only; not an investor transaction price.

Latest filing quarter-end price$496.73Q2 2026

Derived from validated reported value and shares where supported.

Estimated holding basis$358.40Historical reference — not actual purchase price

Calculated from supported filing history.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

View Vertex Pharmaceuticals stock page →

This tracker follows Gotham Asset Management, LLC’s Form 13F disclosures—not Joel Greenblatt’s personal brokerage account. The filing is firm-level rather than a personal stock list. Form 13F reports quarter-end U.S.-listed positions and certain options, but it does not reveal exact trade dates, execution prices, short positions or the purpose of an option position.